The trial is expected to enroll approximately 370 patients who have not had prior treatment for non small cell lung cancer and who will be randomized into either a control group or a treatment group.
The primary objective of this trial is to compare median survival time of patients in the treatment group versus the control group, as well as further defining the safety profile in the treatment group.
“Oxigene’s clinical progress this year, which includes the initiation of this phase III trial, as well as the initiation of a phase II clinical trial in platinum resistant ovarian cancer and the commencement of a phase Ib trial evaluating CA4P in combination with Avastin, demonstrates our clinical focus on oncology and reflects our roadmap for our intended clinical development path,” stated Frederick Driscoll, president and CEO at Oxigene.